Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
about
The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosisTorsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropePro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropeFungal infections associated with contaminated methylprednisolone in Tennessee.Data mining of the public version of the FDA Adverse Event Reporting SystemAssociation of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Overdrive pacing in a patient with incessant torsades de pointes.Voriconazole associated torsades de pointes in two adult patients with haematological malignancies.Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesAssessing the association of pioglitazone use and bladder cancer through drug adverse event reportingAssociation between statin use and cancer: data mining of a spontaneous reporting database and a claims database.Cardiac risks associated with antibiotics: azithromycin and levofloxacinComparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytesUpdate on the cardiac safety of moxifloxacin.The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.Oral fluoroquinolone use and serious arrhythmia: bi-national cohort studyDuloxetine and pregnancy outcomes: safety surveillance findingsEffect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.Multi-factorial causes of torsade de pointes in a hospitalised surgical patient.Cardiovascular and metabolic safety profiles of the fluoroquinolones.Safety of posaconazole.Antibiotic-induced cardiac arrhythmias.A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment.Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database.Drug Fever: a descriptive cohort study from the French national pharmacovigilance database.Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis.Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.Fluoroquinolones and the risk of serious arrhythmia: a population-based study.Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System.Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in KoreaAn investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study
P2860
Q28475461-66E4B346-6590-49FD-9F97-02A04B789149Q28535299-5A391E62-5056-402C-81EA-0685182D953CQ28544621-29F0606B-137E-4116-AC2C-61E52712B53DQ30223895-88B236E1-747A-4708-8891-2D3B59AC39CBQ30651235-81A7D84B-8383-4B90-9A77-F8F2EF128047Q30803396-A35981C9-FBC4-4E41-89A1-4088B7A9C38BQ30852962-1E6C0B2B-1723-41A2-88DC-A71EC378F04DQ33163390-E209A78B-86C9-4E04-A632-AD387469E9C3Q33625746-573734BE-82A2-4B4E-BC1D-8D84E42B0D2DQ33695227-51581B65-BB4E-4D56-8FFA-CD9043B4AE9AQ34336897-8ACB0A5A-E57E-482A-90ED-EC5440A5E661Q34627077-FF2BF2EE-93FD-4EE0-8741-6CA366B8CC8EQ35043204-27A34802-9A63-49A8-B809-ABBDDDBC8735Q35069176-E01C6D9B-87D9-45FB-A368-8CCF7E408C08Q35502601-82B63F59-67AD-49C4-BFA2-D4330DA04D3EQ35708176-1B45735B-71CA-4788-9177-5F1F3F3E44F8Q36345861-99D05FDD-DB99-4740-A298-62ED8E1B75B9Q36460550-55F4136A-C38F-4E31-8C33-97F401E9F837Q36629728-D596DD23-3F1A-4B03-B53F-A045563E18BAQ36663394-5BD51B1C-8571-4DE3-AD9C-692127091CC5Q36667015-EB0912A5-E198-4DBA-A6ED-306D11E1BBC2Q36741055-635B1939-6767-453F-A822-523579B55048Q37940543-A3745371-E01D-48C9-A52C-262CFA68ACD0Q38077591-900815B0-ADA8-41D6-951A-79039A3DA5BBQ38178757-8BB9E02C-73CD-4276-8C9F-145D95DA96E2Q38723257-B8E16F07-3EE0-4BF8-83F5-70B3F0B48D19Q39220049-36EA2999-38E1-4D3C-BE37-DC1AC0C38D5FQ40279591-A5D3E2B9-9637-42E6-9A62-CF382F7BA63FQ42731927-20E18824-2D2E-4F67-98D5-DA46CDD3F3D0Q45330989-E33D59F4-49F1-480E-8B02-9F23E52ECE6DQ46455559-19A3C8A1-CBE4-4D1F-9C7E-6617580037B2Q47237078-60B5E373-2987-42EE-9FD6-A7917CFD55C9Q47300605-1C7477D7-CB50-458D-BCE1-6BD173E4F512Q51495533-1E618869-A18A-41B7-AC0A-E344217112D1Q57212712-920B4359-CE59-4699-A5E7-084B713E207DQ57273964-195DD375-35A2-4311-80FD-BE5ED0454024
P2860
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antimicrobials and the risk of ...... dverse Event Reporting System.
@ast
Antimicrobials and the risk of ...... dverse Event Reporting System.
@en
Antimicrobials and the risk of ...... dverse Event Reporting System.
@nl
type
label
Antimicrobials and the risk of ...... dverse Event Reporting System.
@ast
Antimicrobials and the risk of ...... dverse Event Reporting System.
@en
Antimicrobials and the risk of ...... dverse Event Reporting System.
@nl
prefLabel
Antimicrobials and the risk of ...... dverse Event Reporting System.
@ast
Antimicrobials and the risk of ...... dverse Event Reporting System.
@en
Antimicrobials and the risk of ...... dverse Event Reporting System.
@nl
P50
P1433
P1476
Antimicrobials and the risk of ...... dverse Event Reporting System.
@en
P2093
Ugo Moretti
P304
P356
10.2165/11531850-000000000-00000
P577
2010-04-01T00:00:00Z
P6179
1020464561